Freenome Holdings Inc.
5
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Prevention of Colorectal Cancer Through Multiomics Blood Testing
Role: lead
The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
Role: lead
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Role: lead
The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
Role: lead
AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test
Role: lead
All 5 trials loaded